LIMN - Liminatus Pharma Corp P/S Multiple

Liminatus Pharma is implementing software robots to accelerate the analysis of clinical data. The historical P/S level in the GURU.Markets terminal demonstrates the business valuation trend, where the 0.00 indicator determines the parameter status. The company's revenues are based on the commercialization of CAR-T therapy for solid tumors. Furthermore, financial success relies on the biological achievements of research rather than market cycles.

Liminatus Pharma focuses on developing immunotherapeutic drugs while minimizing operating expenses through production outsourcing. The market capitalization-to-revenue ratio quantifies the value of this intellectual capital relative to current sales. This multiple measures the premium for future growth, helping investors distinguish fundamental undervaluation from a "value trap." By analyzing the P/S chart, one can track the dynamics of market confidence in the company's R&D results.